Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis by Younes, Laurent et al.
r Human Brain Mapping 35:792–809 (2014) r
Regionally Selective Atrophy of Subcortical
Structures in Prodromal HD as Revealed by
Statistical Shape Analysis
Laurent Younes,1 J. Tilak Ratnanather,2 Timothy Brown,3 Elizabeth
Aylward,4 Peg Nopoulos,5 Hans Johnson,5 Vincent A. Magnotta,5
Jane S. Paulsen,5* Russell L. Margolis,6 Roger L. Albin,7 Michael I. Miller,8
Christopher A. Ross9 and the PREDICT-D Investigators and Coordinators
of the Huntington Study Group
1Center for Imaging Science, Institute for Computational Medicine and Department of Applied
Mathematics and Statistics, Johns Hopkins University, WSE, Baltimore, Maryland
2Center for Imaging Science, Institute for Computational Medicine and Department of Biomedical
Engineering, Johns Hopkins University, WSE, Baltimore, Maryland
3Center for Imaging Science, Johns Hopkins University, WSE, Baltimore, Maryland
4University of Washington, Department of Radiology, Seattle Children’s Research Institute,
Seattle, Washington
5Department of Psychiatry, The University of Iowa Carver College of Medicine, Iowa City, Iowa
6Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine,
Baltimore, Maryland
7Department of Neurology, University of Michigan, and VAAAHS Geriatrics Research, Education,
and Clinical Center, Ann Arbor, Michigan
8Center for Imaging Science, Institute for Computational Medicine and Department of Biomedical
Engineering, Johns Hopkins University, WSE, Baltimore, Maryland
9Division of Neurobiology, Departments of Psychiatry, Neurology, Neuroscience and Pharmacology,
and Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine,
Baltimore, Maryland
r r
Abstract: Huntington disease (HD) is a neurodegenerative disorder that involves preferential atrophy
in the striatal complex and related subcortical nuclei. In this article, which is based on a dataset
extracted from the PREDICT-HD study, we use statistical shape analysis with deformation markers
obtained through ‘‘Large Deformation Diffeomorphic Metric Mapping’’ of cortical surfaces to highlight
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specific atrophy patterns in the caudate, putamen, and globus pallidus, at different prodromal stages of
the disease. On the basis of the relation to cortico-basal ganglia circuitry, we propose that statistical shape
analysis, along with other structural and functional imaging studies, may help expand our understanding
of the brain circuitry affected and other aspects of the neurobiology of HD, and also guide the most effec-
tive strategies for intervention. Hum Brain Mapp 35:792–809, 2014. VC 2012Wiley Periodicals, Inc.
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INTRODUCTION
Huntington disease (HD, MIM 143100) is a progressive,
fatal, neurodegenerative disorder that presents with move-
ment disorder, psychiatric features, and cognitive decline
[Harper et al., 2000; Imarisio et al., 2008; Morrison et al.,
2011; Paulson and Albin, 2010; Ross and Tabrizi, 2011;
Warby et al., 2010].
HD is caused by a cytosine–adenine–guanine (CAG) repeat
expansion in the huntingtin gene coding for an expanded
polyglutamine repeat in the huntingtin protein [HD Collabo-
rative Group, 1993]. Motor onset of HD is defined as volun-
tary and involuntary movement abnormalities consistent
with an extrapyramidal movement disorder in an individual
at risk for HD. CAG repeat length is inversely correlated
with age of motor onset, with age dependent penetrance for
repeat lengths between 36 and 40, and then earlier ages of
motor onset for longer repeat lengths above 40.
Because predictive genetic testing is available, there is
now a group of individuals who have tested positive for the
HD triplet repeat expansion, but do not yet have manifest
HD though some may have subtle motor, cognitive, or psy-
chiatric signs (prodromal HD) [Paulsen et al., 2006, 2008;
Tabrizi et al., 2011]. Using the relationship between CAG
repeat length and motor onset age, it is possible to predict
roughly how far a prodromal HD mutant allele carrier is
from expected age of motor onset [Aylward et al., 2004;
Langbehn et al., 2010; Ranen et al., 1995]. Alternatively, it is
possible to define a ‘‘CAP score’’ (using a model including a
CAG-Age Product term [Langbehn et al., 2010]), which
gives an index of the degree of exposure to the toxic poly-
glutamine expansion and correlates inversely with pre-
dicted years to motor onset [Zhang et al., 2011].
HD involves preferential atrophy of the striatal complex
(caudate, putamen, nucleus accumbens) of the basal gan-
glia, and related subcortical nuclei [Vonsattel and Lianski,
1997]. There is atrophy of other brain regions as well,
including substantial atrophy of subcortical white matter
[de la Monte et al., 1988; Lange et al., 1976]. Within the
striatum, there is dramatic loss of the medium spiny projec-
tion neurons, which constitute the great majority of cells in
the striatum with sparing of some populations of striatal
interneurons [Ferrante et al., 1985, 1987a,b]. Neuropatho-
logic studies of HD subjects suggest that striatal atrophy
proceeds in dorsal to ventral and medial to lateral gradients
with initial neuronal loss in the dorsal medial head of the
caudate and dorsal medial putamen. There is also early
neuronal loss in the tail of the caudate [Vonsattel et al.,
1985]. In contrast, there is relative sparing of the nucleus
accumbens and ventral striatum [Ferrante et al., 1986].
Striatal degeneration in HD disrupts cortico-basal gan-
glionic-thalamocortical circuits controlling movement,
thought, and emotions [Albin et al., 1989; Alexander et al.,
1986]. Neurons of deeper layers of some neocortical
regions also degenerate, though not as dramatically as
those in the striatum [Cudkowicz and Kowall, 1990; de la
Monte et al., 1988; Hedreen et al., 1991; Sotrel et al., 1993].
Brain imaging studies have substantially advanced our
knowledge of regional brain atrophy in HD [Aylward
et al., 2004; Douaud et al., 2006; Fennema-Notestine et al.,
2004; Hobbs et al., 2009; Jernigan et al., 1991; Marrakchi-
Kacem et al., 2010; Sritharan et al., 2010; Vandenberghe
et al., 2009; Weaver et al., 2009]. The neurobiological pre-
dictors of huntington’s disease (PREDICT-HD) study is a
longitudinal characterization of these individuals at multi-
ple sites in the US, Europe, and Australia, including struc-
tural brain MRI imaging, and using the CAP score. The
TRACK-HD study is a comparable study at different sites,
in Europe and Canada.
MRI studies of prodromal HD individuals have found
that striatal atrophy begins many years prior to predicted
motor onset [Aylward et al., 2011; Jurgens et al., 2008;
Paulsen et al., 2008, 2010; Squitieri, Cannella et al., 2009;
Tabrizi et al., 2009, 2011]. Cross-sectional and longitudinal
studies [Aylward et al., 2011; Ross and Tabrizi, 2011; Tab-
rizi et al., 2012] indicate that atrophy proceeds relatively
steadily throughout the prodromal HD period, beginning
about 15 years prior to expected motor onset. MRI studies
have indicated that other subcortical structures are
affected, including subcortical white matter, and that in
addition there is atrophy of some regions of cortical gray
matter [Aylward et al., 2011; Hobbs et al., 2010; Stoffers
et al., 2010; Tabrizi et al., 2011]. It has been suggested that
the regions undergoing atrophy can be defined by their
participation in the cortico-basal ganglionic-thalamocortical
circuits [Douaud et al., 2009].
To date, most MRI studies of subcortical gray matter
nuclei have defined a single measure of structural volume.
While this has the advantage of being quantitative, it does
not give specific information about the cell death pattern
in the nuclei. This information would be useful in order to
determine whether MRI morphometric results correlate with
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previous neuropathologic studies, to define better the subre-
gional distribution of atrophy, and for correlation of patho-
logic deviations from the norm with clinical features of HD.
Methods of statistical shape analysis have proved enlight-
ening for studying normal age related variation in subcorti-
cal nuclei and for studying a number of other diseases
[Ashburner et al., 2003; Csernansky et al., 1998, 2000, 2002;
Qiu et al., 2007, 2008, 2009a,b,c, 2010; Thompson et al., 2004;
van den Bogaard et al., 2011; Wang et al., 2007]. We have
now applied statistical shape analysis methods to define re-
gional atrophy within subcortical gray matter nuclei in a
pilot study of a subset of individuals from the PREDICT-
HD study. We find that there is substantial heterogeneity of
atrophy within basal ganglia nuclei. We find that shape
analysis sensitively detects selective atrophy in specific
regions of striatum and globus pallidus. Based on the rela-
tion to cortico-basal ganglia circuitry, we propose that sta-
tistical shape analysis, along with other structural and
functional imaging studies, may help expand our under-
standing of the neurobiology of HD, and also guide the
most effective strategies for intervention.
Our shape analysis pipeline follows a general pattern that
is common to many of other published studies although
specific details vary. Reliable statistical analyses require a
preliminary alignment phase, which produces a generally
high dimensional representation of the data in a coordinate
system in which each coordinate is directly comparable
across shapes. A common approach in this framework is to
register all shapes to a single one, called a template, defining
each anatomy by its relative position with respect to the
template. This operation, described in ‘‘LDDMM-Surface
Registration’’ section, will be done using diffeomorphic
mapping methods. It is important, in this context, to ensure
that the template is as close to the studied population as
possible and it will be defined, in our study, as a population
average along the lines described in ‘‘Template Averaging’’
section. Finally, the statistical analysis itself uses standard
multivariate models, in which significance must be carefully
assessed while considering multiple comparisons. It will be
defined in ‘‘Statistical Analysis’’ section.
METHODS
Data Acquisition and Structure
Datasets were selected from the PREDICT-HD study
where the subjects are at risk for HD (have a parent with
HD) and had previously undergone elective presympto-
matic genetic testing. Prodromal subjects were those that
are found to be gene expanded (CAG length  36) but
had not yet manifested the disease (based on motor diag-
nostic guidelines). Those that were found to be nongene
expanded (CAG at or below 30) were enrolled as compari-
son subjects. There were no subjects with CAG between 30
and 36 used in this analysis. Participants were recruited
from 32 sites across the United States, Canada, Europe,
and Australia and underwent annual study visits consist-
ing of a neurological motor examination, cognitive assess-
ment, brain MRI (biennial), psychiatric and functional
assessment, with blood samples for genetic and biochemical
analyses. Informed written consent was obtained from all
subjects before participating in this study.
Subjects with CAG expansion were divided into three
subgroups (‘‘low,’’ ‘‘mid,’’ and ‘‘high’’) based on their CAP
score defined by their CAG repeat length and current age,
which corresponds to risk for motor onset of HD. The dataset
consisted of 80 subjects, structured as described in Table I.
All scans were obtained using a standard multimodal pro-
tocol from 1.5T scanners. The scanning protocol included a
sagittal localizer, an axial three-dimensional volumetric
spoiled gradient recalled acquisition in steady state sequence
(relaxation time (TR) ¼ 18, excitation time (TE) ¼ 3, field of
view (FOV) ¼ 24, thickness/gap ¼ 1.5/0.0 mm, matrix ¼ 256
 192 with 3=4 phase FOV, number of excitations (NEX) ¼ 2,
flip angle ¼ 20, 124 slices) and a coronal T2/proton density
(PD) sequence (TR ¼ 3,000, TE ¼ 28, FOV ¼ 26, thickness/gap
¼ 3.0/0.0 mm, matrix ¼ 256  192, NEX ¼ 1, flip angle ¼ 90,
64 slices).
Each scan session was processed using the BRAINS
AutoWorkup processing pipeline published in Pierson
et al. [2011]. After completion of AutoWorkup, all scans
were individually inspected and manually corrected where
necessary to ensure correct realignment and coregistration,
tissue classification, and accuracy of brain and subcortical
structures. The resulting preprocessed data included T1,
T2, PD, and tissue classification volumetric images where
the anterior commissure (AC point) was set to be the cen-
ter of the image resampled to 1-mm resolution in a 256 
256  256 matrix along with binary images for the six sub-
structures evaluated in this work (accumbens, caudate,
globus pallidus, hippocampus, putamen, and thalamus).
In preparation for surface-based morphometry (SBM), all
segmented binary volumes were converted into triangu-
lated surfaces using the iso2mesh open source software.
Shape Analysis
Template averaging
Using rigid registration (rotation and translation), each
surface was aligned to a common spatial position. The
rigid registration algorithm computed an optimal transfor-
mation between vertices of two surfaces S0 and S1, by min-
imizing a score combining registration and soft
assignment, given by
TABLE I. Demographic structure of the dataset
Controls Low Mid High Total
Female/Male 10/10 10/6 11/7 17/9 48/32
Mean age
(standard
deviation)
42.8 (10.6) 36.7 (8.9) 41.7 (9.1) 43.3 (8.7) 41.5 (9.5)
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Uðw;R;TÞ ¼
Z
S1S2
wðx; yÞ||Rxþ T  y||2dr1ðxÞdr2ðyÞ
þ k
Z
S1S2
wðx; yÞ lnwðx; yÞdr1ðxÞdr2ðyÞ
In this expression, R and T are a rotation matrix and a
translation vector, respectively; r1 and r2 are area forms
on S1 and S2, respectively; and w is a soft assignment func-
tion defined on S1  S2, and is constrained to be positive,
and to satisfy
Z
S1
wðx0; yÞdr1ðxÞ ¼
Z
S2
wðx; y0Þdr2ðy0Þ ¼ 1
for all (x,y) [ S1  S2. This problem and the associated minimi-
zation algorithm are similar to the ones considered in [Rangar-
ajan et al., 1997]. Right subvolumes were flipped before
alignment to ensure that all structures could be compared.
From rigidly aligned volumes, and for each substructure,
we computed an average shape, or template, using the algo-
rithm described in Ma et al. [2010]. This algorithm computes
the average based on a generative shape model, in which an
observed surface is modeled as a random deformation of a
template, followed by the addition of some colored noise.
Given this model, the template is estimated from data using
an approximation of the expectation-maximization (EM)
algorithm, subject to some topology constraints, which are
enacted by ensuring that the template is a diffeomorphic de-
formation of a reference shape, called hypertemplate (using
a Bayesian viewpoint in which the template is considered as
a random deformation of the hypertemplate). We refer the
reader to Ma et al. [2010] for details.
The resulting templates for the accumbens, caudate,
globus pallidus, hippocampus, putamen, and thalamus are
visualized in Figure 1. They were computed by running
the averaging algorithm on the full population (160 vol-
umes using left and right rigidly registered subvolumes)
and were therefore blind to group labels.
LDDMM-surface registration
The next step computes a nonrigid registration between
the template and all 160 surfaces for a given subvolume. We
used, for this purpose, the large deformation diffeomorphic
metric mapping (LDDMM) surface registration algorithm,
which is described in Vaillant and Glaune`s [2005]. For a
given target surface, this algorithm computes a smooth, in-
vertible transformation that can be applied to the template
(represented as a triangulated surface) to deform it into a
surface that is very close to the target. More precisely, it
minimizes a two-term energy function taking the form
E ¼ distshapeðStemp;SdefÞ2 þ kErrorðSdef;SobsÞ
where Stemp is the template surface, Sobs is the observed
surface, and Sdef is the deformed template, which is esti-
mated by the procedure. The first term, distshape, is a geodesic
distance in shape space, which computes and optimizes a
least-deformation path between two surfaces, the distance
being given by the optimal deformation cost. See Grenander
and Miller [2007]; Mumford and Desolneux [2010]; Younes
[2010] for additional details. The error term, which was intro-
duced in Vaillant and Glaune`s [2005], computes a norm
between surfaces. The construction, based on a mathematical
representation of surfaces in terms of ‘‘geometric currents,’’ is
rather involved and the interested reader is again referred to
Grenander and Miller [2007]; Mumford and Desolneux
[2010]; Younes [2010] for complements.
Statistical Analysis
We performed SBM analyses on each subvolume, in two
different ways. The first set of analyses focused on group
difference, and made separate comparisons of the shape
markers (defined as the degree of atrophy relative to the
template, as measured by shape analysis) between each
group of patients (low, mid, and high CAP scores) and the
control group. The second set replaced group information
by the rank of each subject in terms of CAP scores (and
therefore only focuses on prodromal HD subjects). Both
analyses included age, gender, and intracranial volumes as
covariates; they computed statistics at each vertex of the
triangulated template surface and returned P values cor-
rected for multiple comparisons using permutation tests.
They are described in detail in the next two sections.
Group-based analysis
This first set of results describes how atrophy increased
across patient groups (low, mid, and high) compared to
controls. This analysis was applied separately to each left
or right substructure and progressively added groups with
higher CAP scores. Consider, for example, the analysis of
the left caudate. During the preprocessing phase, each sub-
ject’s left caudate (controls and patients) was registered to
the caudate template, resulting in the computation, at each
vertex k of the template surface, and for each subject s, of
a deformation marker Jk(s) that measured how much
expansion/atrophy at vertex k was measured in the regis-
tration of subject s to the template. Examples of such de-
formation markers are provided in Figure 2. The equations
that follow also include group variables Ylow(s), Ymid(s),
Yhigh(s) equal to 1 if subject s belongs to groups low, mid,
or high in this order, and to zero otherwise.
We progressively added groups in the model to mea-
sure the disease impact at different prodromal HD stages.
Our first model only included controls and low CAP score
group, and was given by (for each vertex k):
JkðsÞ ¼ bk;0 þ bk;lowYlowðsÞ þ
X
cov
acovXcovðsÞ þ ekðsÞ
where the sum refers to covariates (which are gender, age,
and logarithm of intracranial volume), and we tested for
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the null hypothesis bk,low ¼ 0 simultaneously for all k. The
second model added the mid CAP score group, taking the
form
JkðsÞ ¼ bk;0 þ bk;lowYlowðsÞ þ bk;midYmidðsÞ
þ
X
cov
acovXcovðsÞ þ ekðsÞ
in which we tested for the null hypothesis bk,low ¼ bk,mid
¼ 0. Similarly, our third model added the high CAP score
group,
JkðsÞ ¼ bk;0 þ bk;lowYlowðsÞ þ bk;midYmidðsÞ þ bk;highYhighðsÞ
þ
X
cov
acovXcovðsÞ þ ekðsÞ
with null hypothesis bk,low ¼ bk,mid ¼ bk,high ¼ 0.
These models were studied separately, and P values
were computed using permutation sampling. More pre-
cisely, we computed for all k the statistic
Fk ¼ RSS0ðkÞ
RSSðkÞ  1
Figure 1.
Templates computed for each subvolume. Magenta: accumbens; green: caudate; red: globus pallidus;
blue: hippocampus; white: putamen; yellow: thalamus. In this figure and all subsequent ones: from
left to right and top to bottom: anterior, posterior, lateral and medial views; letters A, P, D, V, L,
and M, respectively, refer to anterior, posterior, dorsal, ventral, lateral, and medial directions.
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where RSS0 is the residual sum of squares under the null
hypothesis, and RSS is the sum of squares under the gen-
eral hypothesis, and computed F* ¼ maxkFk, the maximum
value over all vertices. This maximum value was then
compared to those obtained by performing the same com-
putation a large number of times, with group labels ran-
domly assigned to subjects, and the P value was given by
the fraction of times the values of F* computed after per-
muting the labels was larger than the value obtained with
the true groups. The P values that were observed via this
procedure are provided, for each structure and the left
and right sides of the brain, in Table III. (Table II provides
P values for the same model, also evaluated via permuta-
tions, in which J is replaced by the structure volume, for
which no multiple-testing procedure was required).
This permutation testing procedure also provided a
(conservative) estimate of the set of vertices k on which
the null hypothesis was not valid. This set can indeed be
defined by
D ¼ k : Fk  qf g
where q* is the 95 percentile of the observed value of F*
over the permutations [Nichols and Hayasaka, 2003].
Figures 3–6 provide an illustration of these results by col-
oring the vertices that were significant with an atrophy
measure defined as minus the sum of the b coefficients
associated to the considered groups.
Rank-based regression
We also considered a model in which atrophy was pre-
dicted by the rank of each patient in terms of CAP scores
Figure 2.
This figure displays six examples of deformation markers that
were computed on our dataset. Original caudate surfaces are in
red. The first two caudates are controls, followed by two exam-
ples from the mid group and two examples from the high group.
Markers are aligned with the template shape (left shapes) and
measure how much expansion (red) or atrophy (blue) is needed
to deform the template into each of the observed caudates.
TABLE II. P values for volume difference between
groups (controls vs. low, mid, and high CAP scores)
Substructure Low Mid High
Accumbens (Left) 0.01 0.09 0.025
Accumbens (Right) 0.11 0.40 0.18
Caudate (Left) 0.62 0.039 <0.0001
Caudate (Right) 0.55 0.10 <0.0001
Globus Pallidus (Left) 0.05 0.0003 <0.0001
Globus Pallidus (Right) 0.002 0.0003 <0.0001
Hippocampus (Left) 0.77 0.82 0.58
Hippocampus (Right) 0.32 0.62 0.30
Putamen (Left) 0.57 0.0007 <0.0001
Putamen (Right) 0.41 0.037 <0.0001
Thalamus (Left) 0.60 0.51 0.23
Thalamus (Right) 0.79 0.90 0.67
P values are computed separately for each subvolume based on
the model described in ‘‘Group-Based Analysis’’ section.
Moderately significant P values (between 0.001 and 0.05) are
shown in italic, and highly significant P values (less than 0.001)
are shown in boldface.
TABLE III. P values for shape difference between groups
(controls vs. low, mid, and high CAP scores)
Substructure Low Mid High
Accumbens (Left) 0.44 0.25 0.064
Accumbens (Right) 0.37 0.30 0.035
Caudate (Left) 0.91 0.025 <0.0001
Caudate (Right) 0.08 0.14 <0.0001
Globus Pallidus (Left) 0.02 0.001 <0.0001
Globus Pallidus (Right) 0.0042 0.014 <0.0001
Hippocampus (Left) 0.18 0.23 0.18
Hippocampus (Right) 0.64 0.74 0.23
Putamen (Left) 0.33 <0.0001 <0.0001
Putamen (Right) 0.011 0.018 <0.0001
Thalamus (Left) 0.13 0.59 0.17
Thalamus (Right) 0.50 0.66 0.04
P values were computed using rank-based regression (‘‘Rank-
Based Regression’’ section), separately for each subvolume.
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(this evaluation being restricted to prodromal HD patients,
because the CAP score was not defined for controls). In
this setting, each patient, s, was attributed a rank r(s)
between 1 and 60 according to their score. We then fitted
a linear model
JkðsÞ ¼ bk;0 þ bkrðsÞ þ
X
cov
acovXcovðsÞ þ ekðsÞ
and tested for the null hypothesis bk ¼ 0 using permuta-
tion tests similar to the previous section. Results are pro-
vided in Table IV, and Figures 7–10.
RESULTS
These results are summarized by tables of P values
(Tables II–IV), and by figures that describe regions of sig-
nificant atrophy on each subvolume.
Table II provides P values for significant volume differ-
ence between the populations as described in ‘‘Group-
Based Analysis’’ section. Table III provides P values for
SBM shape difference between the populations, still along
the lines of ‘‘Group-Based Analysis’’ section. Table IV pro-
vides corrected P values obtained using rank-based regres-
sion as described in ‘‘Rank-Based Regression’’ section. P
values that are close to 5% in these tables should be taken
with care, since we are not correcting for multiple compar-
ison across structures. They will have to be confirmed in
future studies.
The first remark that can be made is that the three tables
are largely in agreement regarding which structures are
affected or not. The only difference is with the right thala-
mus, for which a mild significance is detected by the SBM
analysis in the high group, whereas such a difference was
not detectable based on volume. This might be due to the
fact that only a small region of the thalamus is found to be
affected, inducing a limited volume difference (relative to
normal population variation).
The agreement between these three tests can be under-
stood by the fact that shape differences in HD are always
caused by volume reduction, which makes them detectable
by a test based on volume, but also seem to concentrate
on consistent locations on surfaces, which makes them de-
tectable by SBM.
At the global level, the P values displayed in Tables II–
IV indicate higher significance in caudate, globus pallidus,
and putamen. Some weak difference (P 0.05) is detected
in the accumbens and in the thalamus, and no significant
atrophy is measured in the hippocampus.
The effects are highly significant within the ‘‘high’’
groups, with several P values below the detectable thresh-
old of 10 4(this threshold being due to the maximal num-
ber of permutations run in our permutations tests, which
is 40,000). A still notable significant effect can be observed
in the ‘‘mid’’ group (left caudate, globus pallidus, and
putamen), and in the ‘‘low’’ group (globus pallidus and
right putamen), although P values get closer to 5% for
these groups.
In addition to global-level significance, SBM identifies
regions of consistent shape differences in each structure.
Figure 3.
Significant atrophy in caudate (high CAP score); each panel contains anterior, posterior, lateral,
and medial views in this order; left: left caudate; right: right caudate.
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Figure 4.
Significant atrophy in globus pallidus. From top to bottom: low, mid, and high CAP scores; left: left globus; right: right globus.
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Figure 5.
Significant atrophy in putamen. From top to bottom: low (right), mid, and high CAP scores; left: left putamen; right: right putamen.
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These regions are visualized in Figures 3–6 for the group-
wise analysis and in Figures 7–10 for the rank-based corre-
lation. In these figures, we only display groups and
volumes for which some significant atrophy has been
measured.
These figures highlight vertices on the surfaces of the
templates at which significant atrophy has been measured
by our tests. Color corresponds to the differential amount
of atrophy in the considered group(s), i.e., the (sum of)
coefficients b in the linear model that correspond to
groups or ranks.
In the striatum, and in subjects with high CAP score, a con-
siderable area of the caudate is affected, with sparing of dorso-
lateral and dorsomedial regions of the mid-body bilaterally. In
the putamen, in the subjects with mid CAP score, shape differ-
ences appear at the anterior dorsomedial left putamen. In sub-
jects with high CAP score, much of the putamen is affected
with some sparing of the most rostral putamen. The nucleus
accumbens was relatively less affected.
The method additionally showed specificity in that the
hippocampus was almost entirely spared until very close
to predicted motor onset. Similarly, the thalamus showed
some variation, but compared with striatum, was rela-
tively spared.
The statistical shape analysis revealed significant differ-
ences within the globus pallidus already in subjects with
low CAP score.
DISCUSSION
In this study, we used statistical shape analysis to define
subregional atrophy in subcortical gray matter in HD. We
describe the changes as ‘‘atrophy,’’ because both PREDICT-
HD and TRACK_HD cross-sectional data show that individ-
uals very far from onset have essentially normal regional
brain volumes (with the proviso that there may be very
subtle developmental differences, e.g., Lee et al., 2012;
Nopoulos et al., 2011, in HD brain development), and longi-
tudinal data from both studies show consistent atrophy in
many brain regions during the period addressed in the cur-
rent study. We find that the method is capable of detecting
differences even in small groups of research subjects far
from predicted motor onset of diagnosable HD. Like volu-
metric measures, statistical shape analysis detects greater
differences in the striatum than in other structures. How-
ever, the subregions of striatum most affected can now be
better defined. In addition, statistical shape analysis (based
on both volume and morphometry) indicates that there are
early differences in globus pallidus in subjects predicted to
be far from motorically manifest HD. The method is likely
to have applicability as a biomarker of brain atrophy in the
prodromal HD period. In future studies, with larger num-
bers of patients, and including diffusion tensor imaging
(DTI), it could help better define the exact circuitry affected
in this disorder.
There are some limitations in the study. The number of
subjects is relatively small, especially when P values are
computed, as done here, using familywise error rates
(which present the advantage of not requiring any addi-
tional assumption on the data, like independence or posi-
tive regression dependence). To see how larger samples
can improve the previous results, we can apply the follow-
ing power analysis. Based on an estimate of 8.0 for the cut
off value of the F-test corrected for multiple comparisons
on our surfaces (the exact value varies between 6.5 and 8.9
on our experiments, depending on the considered struc-
ture), we can estimate that when comparing two groups
with, say, 90 subjects each, we will be able to detect group
difference at a 5% level, and with a power larger than
80%, provided that there exists a point in the structure
such that the ratio l/r is larger than 0.4, where l is the
difference between the group averages of the atrophy
Figure 6.
Significance regions in right thalamus, high CAP score.
TABLE IV. P values for rank-based prediction of atrophy
based on volume only
Subvolume P
Accumbens (Left) 0.049
Accumbens (Right) 0.012
Caudate (Left) <0.0001
Caudate (Right) <0.0001
Globus Pallidus (Left) <0.0001
Globus Pallidus (Right) <0.0001
Hippocampus (Left) 0.12
Hippocampus (Right) 0.02
Putamen (Left) <0.0001
Putamen (Right) <0.0001
Thalamus (Left) 0.08
Thalamus (Right) 0.002
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coefficient (interpreted as a surface area reduction in log
scale) at this point and r is the standard deviation of this
atrophy coefficient at this point (Both l and r being cor-
rected for covariates, age, cranial volume and gender.)
Taking r  0.1 (as observed in our dataset), we can there-
fore expect that the shape analysis will be able to detect
variation of order 4% or more in the atrophy coefficients.
This discussion also applies to group difference resulting
from treatment trials.
The analysis also suffers from the relatively low resolu-
tion of the data, compared to the size of the structures,
especially the accumbens. Also, the tail of the caudate is
not visualized well in this analysis. The study is cross-sec-
tional in design only. As a multicenter study, it has the
advantage of studying subjects from a large area, but this
may increase random variation due to scanners at multiple
sites. Any study of shape has the limitation that it is diffi-
cult to correlate differences in the exterior shape of an ana-
tomic structure with loss of neurons or other atrophic
processes within the structure.
The results of the study overall are in good accord with
previous volumetric studies, in that the most significant
Figure 7.
Significant atrophy in caudate based on CAP ranks; left: left caudate; right: right caudate.
Figure 8.
Significant atrophy in globus pallidus based on CAP ranks; left: left globus; right: right globus.
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and earliest group differences were in the striatum, with
greater striatal deformation closer to predicted motor
onset, as shown either when the subjects were divided
into three groups (based on CAG age product, which cor-
relates highly with estimated years to motor onset), or
when this index was used as a continuous variable. The
statistical shape analysis, in addition, revealed heterogene-
ity within the striatum, as described in the Results section.
This corresponds quite well to previous observations of a
gradient of pathology within the striatum [Vonsattel et al.,
1985]. The nucleus accumbens and ventral striatum are rel-
atively spared in neuropathologic studies, comparable to
our statistical shape analysis [Ferrante et al., 1986].
A recent shape analysis of a subset of prodromal and
HD affected subjects in the TRACK-HD study [van den
Bogaard et al., 2011] found small areas of deviation from
the norm in the prodromal HD subjects, with very few
areas of shrinkage in the far from onset group and a few
scattered areas in the medial portion of the body of the
caudate and putamen, and also the pallidum, in the close
to onset group. These results do not correspond well to
those in our study, but it is difficult to compare, as the
methods are quite different; both methods use distinct
registration algorithms. Shape markers in van den Bogaard
et al. [2011] are based on absolute displacement relative to
a healthy population template, whereas we locally evalu-
ate surface atrophy relative to an average computed from
the global population. The use of LDDMM in our study
might have conferred increased sensitivity. Finally, the sta-
tistical models differ, although both are validated via per-
mutation testing.
Our pallidal results are consistent with the older patho-
logic literature [Albin, Reiner et al. (1990); Deng et al.,
2004; Reiner et al., 1988; Richfield and Herkenham, 1994;
Richfield et al., 1995; Sapp et al., 1995], as well as MRI
results from TRACK-HD and PREDICT-HD [Aylward
et al., 2011; van den Bogaard et al., 2011].
Striatal medium spiny projection neurons are subdi-
vided into subpopulations based on neuropeptide expres-
sion and downstream projection targets. Different
populations of medium spiny neurons project to the exter-
nal segment of the globus pallidus (GPe) and the internal
segment of globus pallidus (GPi), and striato-GPe neurons
degenerate prior to striato-GPi neurons [Albin et al.,
Figure 9.
Significant atrophy in putamen based on CAP ranks; left: left putamen; right: right putamen.
Figure 10.
Significant atrophy in right thalamus based on CAP ranks.
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1990a; Deng et al., 2004; Reiner et al., 1988; Richfield and
Herkenham, 1994; Richfield et al., 1995; Sapp et al., 1995].
Preferential loss of striato-GPe terminals has been docu-
mented in prior case reports of prodromal HD subjects
[Albin, Young et al., 1990, 1992]. The globus pallidus is a
relatively neuron-poor structure with many striatal afferent
terminals and fibers of passage. It is plausible that the pal-
lidal shape differences described here reflect loss of striatal
afferent terminals. The pattern of pallidal shape difference
found in the subjects with high CAP score (Fig. 4, third
panel) suggests relatively sparing of portions of the medial
globus pallidus, a result consistent with the pathologic
results indicating preferential loss of striato-GPe afferent
terminals. Our pallidal shape results are consistent also
with the recent MRI study of [Douaud et al., 2009] who
studied integrity of white matter tracts in a small number
of manifest HD subjects. This group reports results consist-
ent with substantial loss of putaminal–pallidal projections.
The observations of basal ganglia atrophy with heterogene-
ous distribution raise the possibility that statistical shape anal-
ysis could be used to help define in more detail the neural
circuitry affected in HD. Previous studies have used DTI in
order to define potential circuitry [Douaud et al., 2009]. No
DTI scans were available from our subjects. However, one
can begin to make correlations based on the regional hetero-
geneity of atrophy seen in the study, and a presumed role of
corticostriatal circuitry in degeneration. Previous studies of
cortical gray matter [Nopoulos et al., 2010; Rosas et al., 2008]
have indicated that cortical gray matter atrophy begins ear-
liest in occipital, parietal, superior temporal, and dorsolateral
frontal cortices. Corticostriatal projection anatomy has a com-
plex topology, including elements of somatotopic organiza-
tion, projections from cortical fields in rostral-caudal
parasagittal zones, and some convergence of projections from
anatomically separate but functionally related cortical regions
[Haber and Knutson, 2009; Kemp and Powell, 1970; Selemon
and Goldman-Rakic, 1985; Yeterian and Van Hoesen, 1978].
Our observed pattern of striatal shape deformations
appears to overlap partly with the pattern of abnormal devia-
tions in the cortex. For example, Nopoulos et al. [2010] found
relative sparing of ventromedial and orbitofrontal frontal cor-
tices, which would correlate with relative lack of shape varia-
tion in the nucleus accumbens and ventral caudate-putamen,
and early differences in occipital and parietal cortical vol-
umes in subjects approximately comparable to our mid CAP
score subjects, which could correlate with shape differences
seen in left caudal dorsolateral caudate [Cavada and Gold-
man-Rakic, 1991; Yeterian and Pandya, 1993, 1995].
However, other changes in basal ganglia do not corre-
spond well with changes in cortex. Nopoulos et al. [2010]
describe also the presence of dorsolateral frontal cortex at-
rophy. A correlated deviation in striatal shape is predicted
to manifest in dorsomedial caudate [Haber and Knutson,
2009; Kemp and Powell, 1970; Selemon and Goldman-
Rakic, 1985], which is not seen. Similarly, Nopoulos et al.
[2010] find significant atrophy of primary sensorimotor
cortex in subjects similar to our high CAP score subjects. If
cortical volume decrement and striatal shape deformations
were correlated closely [Kemp and Powell, 1970; Kunzle,
1975, 1977; Selemon and Goldman-Rakic, 1985], the more
rostral dorsolateral and dorsomedial caudate would ex-
hibit a difference in shape, which is not the case. It maybe
that some correlated deviations are not visualized in our
analysis, as occipital and parietal cortices project heavily
to the relatively small tail of the caudate, which is not
measurable in our analysis.
Thus, while it is possible that striatal atrophy is secondary
or concurrent with cortical atrophy, it is also possible that the
two processes proceed relatively independently. This would
be consistent with recent studies showing substantial white
matter atrophy in many regions of the brain, not just in regions
subjacent to those of cortical gray matter loss [Stoffers et al.,
2010]. This point may be relevant to understanding the mech-
anisms of pathogenesis of striatal neurodegeneration in HD
and potential therapies. One proposed family of mechanisms
of neurodegeneration are ‘‘cell nonautonomous’’ sequences
in which corticostriate neuron dysfunction or death leads to
striatal neuron dysfunction or death. For instance, there may
be loss of trophic support because of deficient brain-derived
neurotrophic factor secretion by or transport to corticostriate
terminals [Zuccato and Cattaneo, 2009]. Our finding of only
partial congruence with patterns of cortical atrophy suggests
a more complex picture in which both cell autonomous and
nonautonomous mechanisms are involved. Plurality of
mechanisms would be consistent with some experimental
results in murine genetic models of HD [Brown et al., 2008;
Gu et al., 2005]. Further studies examining cortical variations
and striatal shape differences in parallel and in larger num-
bers of subjects would address this point.
This question of the involvement of circuitry in HD is
an important one. If the degeneration in HD, like that of
Alzheimer’s and perhaps Parkinson’s disease [Braak et al.,
2003], starts in a very restricted location—for instance, the
striatum—and then proceeds in a circuit-based fashion, this
would offer the hope that gene therapy (perhaps using viral
vectors injected into these regions) or transplantation
approaches could be effective at aborting the disease pro-
cess before it spreads further in the brain. By contrast, if
degeneration in HD is multifocal and does not proceed
purely on the basis of neuronal circuitry, that would require
much more widespread administration of gene therapeutic
agents, or would favor systemic small molecule therapy,
which would be able to penetrate more widely throughout
the brain. Thus, statistical shape analysis, along with other
structural and functional imaging studies in a larger num-
ber of subjects, especially with a longitudinal design, may
help expand our understanding of the neurobiology of HD,
and also guide the most effective strategies for intervention.
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